Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Bank of america - The Real Truth

Ignore the Foundry Fears and Keep Buying Taiwan Semi Stock

As AI demand surges, Bank of America believes investors should ignore the competitive noise and keep buying Taiwan Semi stock.

Barchart

J.B. Hunt Says Freight Rates Are Rising as Capacity Tightens, Not Demand

Executives from J.B. Hunt Transport Services (NASDAQ:JBHT) said freight-market conditions are tightening, but they attributed much of the shift to capacity leaving the market rather than a broad-based demand rebound. Speaking at a Bank of America transportation conference, Brad Hicks, executive vic

MarketBeat

Stanley Druckenmiller Dumps Alphabet After Boosting Stake 277% Last Quarter — Here's What He's Buying Now

Stanley Druckenmiller's Duquesne Family Office sold its entire Alphabet stake in Q1 despite impressive returns amid concerns over AI competition and regulatory pressures.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended

MarketBeat

Integra LifeSciences Says Transformation Is Working as SurgiMend Relaunch Nears

Integra LifeSciences (NASDAQ:IART) is keeping its core strategy intact following a leadership change that returned Stuart to the roles of chairman and chief executive officer, Chief Financial Officer Lea Knight said during a Bank of America med tech conference discussion hosted by analyst Rei Tan.

MarketBeat

Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness

Henry Schein (NASDAQ:HSIC) executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season. Speaking at a Bank of America h

MarketBeat

GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead

GRAIL (NASDAQ:GRAL) said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company’s CFO, at a Bank of America event. Aaron said t

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference

Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and colorectal cancers during a Bank of America biotech conference session. Jonathan Lim, Erasca’s chair

MarketBeat

Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval

Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and Chief Financial Officer Alexander Schuth said at a Bank of America Securities conference. Speaking

MarketBeat

CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host

MarketBeat

Akamai Stock Is Surging on an Analyst Upgrade. It’s No Longer a Legacy Tech Company.

Akamai stock is soaring as Bank of America says the company is rapidly emerging as a major AI infrastructure player, boosting its price target to $175.

Barchart

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam Meyers, head of the company’s immunology and new disease areas franchise, said at Bank of America’s

MarketBeat

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference. Ryan Kohlhepp of

MarketBeat

Why Bank of America Is Betting Big on ASML Stock as Trump-Xi Meet

As Trump and Xi meet in Beijing, ASML stock is expected to emerge as a key winner from any easing in U.S.-China chip tensions.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

This Analyst Just Upgraded Akamai Technologies. Here's Why.

Akamai stock rallies as Bank of America raises its price target to $175. Here’s why BofA is constructive on AKAM shares for the remainder of 2026.

MarketBeat

AeroVironment CEO Says Drone Warfare Shift Is ‘Our Moment’ as Defense Demand Builds

AeroVironment (NASDAQ:AVAV) Chairman, President and CEO Wahid Nawabi said accelerating global security threats are reshaping defense priorities toward drones, loitering munitions and counter-unmanned aircraft systems, areas where he said the company is well positioned. Speaking at a Bank of America

International Business Times UK

Nvidia Heads Into 20 May Earnings With a $5.3 Trillion Valuation — Growth Must Stay 'Historically Impossible'

Nvidia's upcoming Q1 FY2027 earnings report is anticipated to show strong growth, driven by AI infrastructure demand. Analysts remain optimistic despite the company's high market valuation.

MarketBeat

Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference

Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses. Gaggar describe

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

If you used a Bank of America card at a 7-Eleven ATM, you are eligible to receive money after settlement

The disputed fees were charged at FCTI-owned 7-Eleven ATMs between May 1, 2018, and November 16, 2021

MarketBeat

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches and prescriber expansion as key drivers for the rest of the year

Barchart

Nebius Just Soared to a New 52-Week High. Here's What to Know.

Nebius shares are rallying as the company reported blockbuster Q1 financials – and even beyond headline numbers, there are ample reasons to load up on NBIS shares today.

International Business Times UK

Chicago Man Told to Take Money Out of Bank of America by Fake US Marshals After Apple Call — Loses $69,000

A Chicago man lost $69,000 (£51,000) to scammers using AI-generated images. The incident underscores the increasing sophistication of scams and the need for vigilance.

MarketBeat

Astrana Health Says Prospect Deal Is Ahead of Schedule as Q1 Trends Beat Expectations

Astrana Health (NASDAQ:ASTH) CEO and President Brandon Sim said the value-based care company is seeing early benefits from its acquisition of Prospect, while reporting stronger-than-expected first-quarter trends across medical costs, free cash flow and revenue. Speaking at a Bank of America healthc

MarketBeat

AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook

AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management. Speaking at a Bank of America fireside

MarketBeat

AdaptHealth Conference: Kaiser Deal Drives Growth, Labor Costs Dent EBITDA

AdaptHealth (NASDAQ:AHCO) told investors at a Bank of America event that first-quarter results reflected broad organic growth across its business lines, but also higher-than-expected labor costs tied to a major capitated contract transition. Bank of America analyst Joanna Gajuk opened the discussio

1 2 3 4 5

People

Stanley Druckenmiller

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.